SPRY
ARS Pharmaceuticals Inc.
$9.40
+$0.90(+10.59%)
40
Overall
50
Value
36
Tech
34
Quality
Market Cap
$888.65M
Volume
2.61M
52W Range
$6.66 - $18.90
Target Price
$23.75
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $5.5M | $1.3M | $30.0K | $89.1M | $84.3M | ||
| Total Revenue | $5.5M | $1.3M | $30.0K | $89.1M | $84.3M | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | -- | -- | -- | $977.0K | -- | ||
| GROSS PROFIT | |||||||
| Gross Profit | $5.5M | $1.3M | $30.0K | $89.1M | $84.3M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $25.0M | $36.8M | $67.5M | $92.2M | $263.7M | ||
| Research & Development | $20.3M | $18.4M | $20.3M | $19.6M | $13.2M | ||
| Research Expense | $20.3M | $18.4M | $20.3M | $19.6M | $13.2M | ||
| Selling, General & Administrative | $4.7M | $18.5M | $47.3M | $71.7M | $230.1M | ||
| Selling & Marketing Expenses | $476.0K | $603.0K | -- | $12.5M | -- | ||
| General & Administrative Expenses | $4.7M | $18.5M | $47.3M | $71.7M | $230.1M | ||
| Depreciation & Amortization | $800.0K | $100.0K | $100.0K | $100.0K | -- | ||
| Depreciation & Amortization | $800.0K | $100.0K | $100.0K | -- | -- | ||
| Amortization | $2.0K | -- | -- | $7.4M | -- | ||
| Other Operating Expenses | $-206.0K | $-373.0K | $-475.0K | $92.2M | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-19.5M | $-35.5M | $-67.5M | $-3.1M | $-179.4M | ||
| EBITDA | $-20.2M | $-35.2M | $-67.5M | $8.4M | $-170.0M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $-106.0K | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $106.0K | -- | -- | -- | -- | ||
| Gain on Sale of Securities | -- | $-140.0K | -- | -- | -- | ||
| Other Income/Expense | $789.0K | $834.0K | $-13.2M | $-11.4M | $-8.1M | ||
| Other Special Charges | $-789.0K | $974.0K | $13.2M | $11.4M | $8.1M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-20.2M | $-35.5M | $-67.5M | $8.3M | $-171.4M | ||
| Pre-Tax Income | $-20.2M | $-34.7M | $-54.4M | $8.3M | $-171.4M | ||
| INCOME TAX | |||||||
| Tax Provision | $-9.0K | $-21.0K | $-88.0K | $288.0K | $-80.0K | ||
| NET INCOME | |||||||
| Net Income | $-20.2M | $-34.7M | $-54.4M | $8.0M | $-171.3M | ||
| Net Income (Continuing Operations) | $-20.2M | $-34.7M | $-54.4M | $8.0M | $-171.3M | ||
| Net Income (Discontinued Operations) | $-20.2M | $-34.7M | $-54.4M | $8.0M | $-171.3M | ||
| Net Income (Common Stockholders) | $-20.2M | $-34.7M | $-54.4M | $8.0M | $-171.3M | ||
| Normalized Income | -- | -- | -- | -- | $-171.5M | ||
| TOTALS | |||||||
| Total Expenses | $25.0M | $36.8M | $67.5M | $92.2M | $263.7M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $34.9M | $40.0M | $95.2M | $96.9M | $98.6M | ||
| Average Shares Outstanding (Diluted) | $34.9M | $40.0M | $95.2M | $102.4M | $98.6M | ||
| Shares Outstanding | $35.1M | $94.4M | $96.5M | $98.1M | $99.3M | ||
| Basic EPS | $-2.56 | $-0.87 | $-0.57 | $0.08 | $-1.74 | ||
| Basic EPS (Continuing Operations) | $-2.56 | $-0.87 | $-0.57 | $0.08 | $-1.74 | ||
| Diluted EPS | $-2.56 | $-0.87 | $-0.57 | $0.08 | $-1.74 | ||
| Diluted EPS (Continuing Operations) | -- | $-0.87 | $-0.57 | $0.08 | $-1.74 | ||
| OTHER METRICS | |||||||
| Other Gand A | $4.7M | $18.5M | $47.3M | $71.7M | $230.1M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SPRY | $9.40 | +10.6% | 2.61M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ARS Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW